Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Retained Earnings (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Retained Earnings for 4 consecutive years, with -$1.3 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 16.31% to -$1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.3 billion through Dec 2025, down 16.31% year-over-year, with the annual reading at -$1.3 billion for FY2025, 16.31% down from the prior year.
  • Retained Earnings hit -$1.3 billion in Q4 2025 for Axsome Therapeutics, down from -$1.3 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$448.8 million in Q1 2022 to a low of -$1.3 billion in Q4 2025.
  • Historically, Retained Earnings has averaged -$873.7 million across 4 years, with a median of -$869.7 million in 2023.
  • Biggest five-year swings in Retained Earnings: crashed 48.78% in 2024 and later decreased 16.31% in 2025.
  • Year by year, Retained Earnings stood at -$596.3 million in 2022, then tumbled by 40.12% to -$835.6 million in 2023, then tumbled by 34.37% to -$1.1 billion in 2024, then dropped by 16.31% to -$1.3 billion in 2025.
  • Business Quant data shows Retained Earnings for AXSM at -$1.3 billion in Q4 2025, -$1.3 billion in Q3 2025, and -$1.2 billion in Q2 2025.